ABLX.BR - Ablynx NV

Brussels - Brussels Delayed Price. Currency in EUR
+0.255 (+1.582%)
At close: 5:35PM CEST
Stock chart is not supported by your current browser
Previous Close16.120
Bid11.210 x 30000
Ask11.890 x 150000
Day's Range16.120 - 16.635
52 Week Range8.211 - 18.280
Avg. Volume322,681
Market Cap1.01B
PE Ratio (TTM)-20.22
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters19 days ago

    Belgian biotech Ablynx scores big hit with blood disease drug

    Ablynx said its caplacizumab medicine met the primary and secondary goals in a late-stage trial testing the treatment in patients with acquired thrombotic thrombocytopenic purpura (aTTP). This included a 74 percent relative reduction in the percentage of patients with aTTP-related death, a recurrence of aTTP or at least one major thromboembolic event during the study drug treatment period. Shares in Ablynx jumped 25 percent in early trade on what Jefferies analysts described as near best-case results.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ABLX.BR earnings conference call or presentation 24-Aug-17 2:00pm GMT

    Half Year 2017 Ablynx NV Earnings Call

  • We're sorry this is all we were able to find about this topic.